Wall Street Zen Upgrades Cyclerion Therapeutics (NASDAQ:KRSA) to Sell

Cyclerion Therapeutics (NASDAQ:KRSA) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

KRSA has been the subject of a number of other research reports. Stifel Nicolaus started coverage on Cyclerion Therapeutics in a research report on Monday, September 14th. They set a “buy” rating and a $43.00 price target for the company. TD Cowen started coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They issued a “buy” rating on the stock. UBS Group initiated coverage on shares of Cyclerion Therapeutics in a research note on Friday, September 11th. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday, September 9th. Finally, Guggenheim began coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 28th. They issued a “buy” rating and a $70.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $56.00.

Cyclerion Therapeutics Price Performance

NASDAQ:KRSA opened at $30.49 on Friday. Cyclerion Therapeutics has a 52-week low of $7.19 and a 52-week high of $59.36. The firm has a market cap of $20.43 million, a P/E ratio of -2.62 and a beta of 1.72.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.